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Abstract
Aims/hypothesis Approximately 10% of total healthcare budgets worldwide are spent on treating diabetes and its complications,
and budgets are increasing globally because of ageing populations and more expensive second-line medications. The aims of the
study were to estimate the within-trial and lifetime cost-effectiveness of the weight management programme, which achieved
46% remissions of type 2 diabetes at year 1 and 36% at year 2 in the Diabetes Remission Clinical Trial (DiRECT).
Methods Within-trial analysis assessed costs of the Counterweight-Plus intervention in DiRECT (including training, programme
materials, practitioner appointments and low-energy diet), along with glucose-lowering and antihypertensivemedications, and all
routine healthcare contacts. Lifetime cost per quality-adjusted life-year (QALY) was estimated according to projected durations
of remissions, assuming continued relapse rates as seen in year 2 of DiRECT and consequent life expectancy, quality of life and
healthcare costs.
Results Mean total 2 year healthcare costs for the intervention and control groups were £3036 and £2420, respectively: an
incremental cost of £616 (95% CI –£45, £1269). Intervention costs (£1411; 95% CI £1308, £1511) were partially offset by
lower other healthcare costs (£796; 95% CI £150, £1465), including reduced oral glucose-lowering medications by £231 (95%
CI £148, £314). Net remission at 2 years was 32.3% (95%CI 23.5%, 40.3%), and cost per remission achieved was £1907 (lower
95% CI: intervention dominates; upper 95% CI: £4212). Over a lifetime horizon, the intervention was modelled to achieve a
mean 0.06 (95% CI 0.04, 0.09) QALY gain for the DiRECT population and mean total lifetime cost savings per participant of
£1337 (95% CI £674, £2081), with the intervention becoming cost-saving within 6 years.
Conclusions/interpretation Incorporating the lifetime healthcare cost savings due to periods of remission from diabetes and its
complications, the DiRECT intervention is predicted to be bothmore effective (QALY gain) and cost-saving in adults with type 2
diabetes compared with standard care. This conclusion appears robust to various less favourable model scenarios, providing
strong evidence that resources could be shifted cost-effectively to support achieving remissions with the DiRECT intervention.
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DiRECT Diabetes Remission Clinical Trial
GP General practitioner
NHS National Health Service
QALY Quality-adjusted life-year
QoL Quality of life
SCI-Diabetes Scottish Care Information Diabetes
Database
Introduction
Type 2 diabetes, until recently considered a permanent and
inevitably progressive chronic disease, impacts rates of
mortality and morbidity as well as quality of life (QoL).
Affecting between 5% and 35% of post-industrial adult popu-
lations [1], it presents a major and increasing economic
burden, currently accounting for 10% of total healthcare
expenditure in the UK [2] and 12.5% in the USA [3].
Management has usually focused on pharmacotherapy, with
increasing emphasis in guidelines on earlier prescription of
more modern and expensive glucose-lowering, lipid-
lowering and antihypertensive drugs, to control blood glucose
and reduce the associated complications and elevated cardio-
vascular risks. Despite these treatments, younger people, in
particular, commonly face irreversible declines in health from
type 2 diabetes, characterised by chronic pain and multiple
disabilities, and life expectancy is reduced substantially [4].
However, remission of type 2 diabetes is now known to be
possible [5–7]. In the Diabetes Remission Clinical Trial
(DiRECT), an integrated diet programme delivered entirely
within primary care produced remissions of type 2 diabetes
(non-diabetic HbA1c on no glucose-lowering medication) in
46% of participants at 1 year and 36% at 2 years [8, 9].
The DiRECT study, reported in detail elsewhere [8, 10],
recruited 298 adults with a diagnosis of diabetes within the
past 6 years, BMI 27–45 kg/m2 and HbA1c >48 mmol/mol
(6.5%), or >42 mmol/mol (6.0%) if receiving glucose-
lowering medication. Half the participants were in practices
randomised to receive the Counterweight-Plus weight
management programme, and all received usual care under
current clinical guidelines. The Counterweight-Plus
programme is initiated as ‘total diet replacement’ with a
low-energy formula diet (soups and shakes) providing
3452–3569 kJ (825–853 kcal) per day for 12–20 weeks
(Counterweight, UK). This is followed by structured food
reintroduction for 2–8 weeks and a subsequent longer-term
programme of weight loss maintenance. For relapse manage-
ment, 2–4 week ‘rescue packages’ of the formula diet are
provided if >2 kg weight is regained or if diabetes returns.
All oral glucose-lowering and antihypertensive medications
are suspended on safety grounds at the start of the programme
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but are reintroduced according to blood glucose and blood
pressure measurements taken at each primary care appoint-
ment, following clinical guidelines.
Remission of type 2 diabetes has the potential to lead to
substantial long-term health gains and cost savings. Decision
analytic models are commonly used to extrapolate long-term
costs and outcomes from clinical trials, supplementing trial
data with other sources of evidence on longer-term disease
progression such as diabetes relapse, health-related QoL,
mortality and costs [11]. Here we report a lifetime cost-
effectiveness analysis of the Counterweight-Plus intervention,
based on resource use measured in DiRECT over 2 years, and
projected longer-term cost and quality-adjusted life-years
(QALYs), assuming a limited duration of diabetes remission.
Methods
A within-trial cost analysis was conducted using the 2 year
data from DiRECT, including both the intervention costs and
routine healthcare resource use measured during the time
course of the study, for all participants (including those who
did not complete the trial or who were unsuccessful in achiev-
ing remission). Lifetime cost-effectiveness was then estimated
by predicting time to relapse (i.e. re-emergence of diabetes,
assumed to be permanent thereafter) among those whowere in
remission at 2 years, applying the mean management costs for
type 2 diabetes incurred within the UK National Health
Service (NHS), under clinical guidelines which tend to favour
older, less expensive medications. An NHS perspective for
costing was adopted for both within-trial and lifetime analy-
ses. Costs are presented in 2018 UK prices (£).
Ethics approval Ethics approval was granted in January 2014
by the West of Scotland Research Ethics Committee 3, with
approvals by the NHS health board areas in Scotland and by
clinical commissioning groups in Tyneside, UK.
Two year within-trial economic analysisDiRECT intervention
costs over the 2 year trial period included costs for initial
Table 1 Intervention resource use components and cost (per participant) (n = 149) over the first 2 years of the DiRECT trial
Intervention cost components Quantity Unit costa (£) Total cost (£) 95% CIb
Intervention set-up cost (overall)
Counterweight-Plus specialist training, support and mentoring 33 practitioners 300/practitioner 9900
Practice nurse and dietitian time 16 h/practitioner 42/h 22,176
Total set-up cost 32,076
Total set-up cost annualised over 5 yearsc 7104
Total intervention set-up cost per participant 48
Intervention running resource use and costs (per participant)d
Sachets issued 20/14 sachets
Year 1 495 (458, 532) 708 654, 760
Year 2 95 (76, 112) 130 104, 155
Overall 590 (539, 639) 838 766, 908
Practice nurse or dietitian visitsd 42/h (25–35 min/appointment)
Year 1 15.6 (14.6, 16.6) 362e 337, 384
Year 2 7.7 (6.7, 8.6) 144e 125, 164
Overall 23.0 (21.4, 25.1) 506 464, 545
Counterweight-Plus booklets (year 1 only) 1 20/participant 20 –
Total intervention running cost per participant 1364 1260, 1464
Total intervention cost per participant (n = 149f)
Year 1 1137 1071, 1205
Year 2 274 234, 313
Overall 1411 1308, 1511
aUnit cost £42/h for practice nurse or dietitian visits [13]; unit cost for intervention materials obtained from the DiRECT trial team
b 95% CI from 1000 bootstrap iterations
c Annualised total cost over 5 years: K/[(1 − 1/(1 + r)n )/r], where K = £32,076, r = 3.5%, n = 5
dValues in the ‘Quantity’ column are mean (95% CI)
e Costed based on recorded duration of contacts (in minutes); year 2 cost discounted
f Includes six randomised participants who did not initiate the intervention
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training of practitioners (dietitians or nurse practitioners, who
each received a total of 16 h face-to-face training from
Counterweight-Plus instructors), sachets of low-energy
formula diet, practitioner monitoring appointments and the
tailored Counterweight-Plus workbooks issued to each partic-
ipant (Table 1). Costs of the sessions included practitioners’
attendance time and standard Counterweight-Plus materials.
The number of sachets issued to each participant and the
number and duration of practitioner appointments were
collected prospectively throughout the study. Full costs for
participant Counterweight-Plus workbooks were applied irre-
spective of participants’ persistence with the programme, the
details of which are described elsewhere [8, 10, 12].
Details of all primary and secondary care visits for each of
the participants were obtained directly from the participating
general practitioner (GP) practice records. The costs of these
were calculated using the recorded duration of contact for each
appointment. Medication use was costed based on dose,
frequency and start and end dates of individual participants’
medication records in each participating GP practice.
Hospitalisation costs were estimated by matching reason for
admission and recorded length of stay in DiRECT to the
appropriate NHS reference cost (excluding excess bed-days,
where length of stay recorded in DiRECT exceeded the
national average). Unit costs were obtained from published
national sources (Personal Social Service Research Unit
[13], NHS reference costs [14], or Information Services
Division Scotland [15], and British National Formulary [16])
and have been reported previously [17].
Statistical analysis was conducted based on the intention-
to-treat principle. Missing data were minimal, as all resource
use data were obtained directly from participating GP prac-
tices. Five intervention (3%) and three control (2%) partici-
pants relocated with loss to follow-up during the study. Their
medication use was assumed to continue as at their last avail-
able records, and other healthcare resource use was assumed
to be zero after relocation. Twenty intervention (13.4%) and
six control (4%) participants had no data available for the
2 year remission outcome. In line with the primary outcome
analysis, these participants were assumed not to have achieved
remission.
Mean costs were calculated for each group, with clustering-
adjusted SEs for each cost item. Incremental cost per remis-
sion at 2 years was reported as the difference in the groups’
total 2 year costs, divided by the difference in diabetes remis-
sion rates. All analyses were undertaken in Stata/MP, version
14.2 (StataCorp LP, USA), with 95% CIs based on 1000 non-
parametric bootstrap iterations.
Long-term projection Long-term outcomes were projected for
each treatment arm in DiRECT. A three-state model (remis-
sion, diabetes, death) was constructed. Individuals enter the
model with existing diabetes. After 1 year a proportion
achieve remission but are subject to relapse in future years.
The proportion remaining in remission over time was estimat-
ed based on the rate of relapse observed in year 2; however, all
participants were assumed to relapse after a given number of
years (a maximum period of 10 years of remission in the base
case). Life expectancy was calculated for each potential year
of remission by applying rates of mortality for people free of
diabetes up to the year of relapse and with diabetes thereafter.
Along with life expectancy, quality-adjusted life expectancy
and healthcare costs were estimated conditional on each
potential year of relapse.
Life expectancy was calculated based on rates of mortality
in people free of diabetes (N = 2.75 million) and with diabetes
(N = 272,597), based on a recent UK study [18] which report-
ed mortality rates by sex and 5 year age bands during the
period 2012–2014 in Scotland. Reported life expectancy for
men aged 55–59 years was 23.0 and 26.0 years with diabetes
and free of diabetes, respectively, and 24.4 and 28.7 for
women.
QALYs were calculated by applying standard UK age-
dependent health state utility population norms [19]. These
were assigned directly to people in remission from diabetes.
For people not in remission, including those who had
relapsed, these age-dependent health state utilities were
reduced using a constant multiplier of 0.925 to reflect a decre-
ment due to diabetes. This was estimated based on the mean
population score (0.828) and the regression coefficient for
diabetes (−0.0621) in the US Medical Expenditure Panel
Survey catalogue of UK EuroQol EQ-5D scores [20]. This
estimate was employed rather than being based on data from
DiRECT, for reasons discussed below.
The lifetime healthcare costs associated with diabetes were
compiled first from the measured costs for the first 2 years of
DiRECT, to which were added further costs for ongoing
weight management for participants remaining in remission
and long-term healthcare costs associated with diabetes.
Long-term diabetes-related healthcare costs were assumed to
increase linearly with duration of diabetes (i.e. time since
relapse), over 15 years, from £1250 in the year of diagnosis
to £3117 after 15 years, based on a UK cost of diabetes study
[2, 21]. No further increase in long-term healthcare costs
beyond 15 years was applied. Long-term healthcare costs
due to diabetes were applied to the proportion of people
projected to be in the diabetes state each year after year 2.
We compared the incremental cost and QALYs for the
intervention and control arms over the 2 year follow-up of
DiRECT and over a lifetime horizon. Sensitivity analysis
was undertaken for the long-term analysis, including explor-
ing the impact of alternative relapse rates and maximum
assumed durations of diabetes remission. Probabilistic sensi-
tivity analysis was performed using 1000 bootstrap iterations
of the DiRECT data (remission and 2 year costs), and Monte
Carlo simulations for other variables (e.g. long-term mortality
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rates). Model input data are summarised in Table 2; all costs
and outcomes beyond year 1 were discounted at the standard
UK annual rate of 3.5%.
Results
Within-trial results During the first year of the DiRECT inter-
vention, a mean of approximately 500 sachets of low-energy
formula diet were issued to each participant, over 80% of the
total 2 years’ consumption being consumed during the initial
total diet replacement phase (Fig. 1). Each participant received
a mean of 23 practitioner visits, the majority of these also
during year 1. The cost of formula diet and practice visits
together was £1364 (95% CI £1260, £1464) per participant
entered over 2 years, and total intervention costs, including
amortised clinic set-up costs, amounted to £1411 (95% CI
£1308, £1511).
The focus and resource need of the Counterweight-Plus
programme shifts from weight loss using total diet replace-
ment in the initial 12–20 weeks to long-term weight mainte-
nance, with data currently available for 2 years (Table 1, Fig.
1). Use of formula diet sachets in year 2 was limited to regular
maintenance, for those who elected to use them, and for
relapse management purposes (when participants regained
over 2 kg body weight). Their total use amounted to less than
20% of the year 1 consumption, when they were used for total
diet replacement, and decreased over the food reintroduction
phase. Similarly, planned practitioner appointments in year 2,
for maintenance and relapse management, were approximate-
ly 50% fewer than in year 1.
Participants in the intervention group had substantially
fewer days on oral glucose-lowering and antihypertensive
drugs. Over the 2 years, participants in the intervention group
had a mean of 290 days on oral glucose-loweringmedications,
compared with 910 for those in the control group (difference
620 days; 95% CI 501, 738), and a mean of 381 days on
antihypertensive medications, compared with 782 for those
in the control group (difference 410 days; 95% CI 258, 537)
(Table 3). The intervention group had fewer GP visits related
to diabetes (difference 0.6 visits; 95%CI 0.2, 1.0). Other items
of resource use were mostly lower in the intervention arm,
including fewer hospital days. Lower use of glucose-
lowering and antihypertensive medications, combined with
fewer healthcare contacts, provided total savings in the inter-
vention arm over 2 years of £796 (95% CI £150, £1465). This
cost saving in routine (non-trial) resource use offset 56% of the
2 year intervention costs, leaving a 2 year incremental cost for
the intervention of £616 (95% CI –£45, £1269) per participant
entered. Given remission rates of 35.6% and 3.4% in the inter-
vention and control arms, respectively, at 2 years, the resulting
incremental cost per remission at 2 years was £1907 (lower
95% CI: intervention dominates, i.e. is cost-saving and more
effective; upper 95%CI: £4212). Medication cost savings were
principally due to lower use of glucose-lowering medicines
(approximately 90% of total medication savings) and were
Table 2 Variable values for the
long-term economic model Variable Value 95% CI or SE Source
Male, % 59 DiRECT [8]
Age, years 54 DiRECT [8]
Remission (year 1) intervention, % 45.6 37.6, 53.0 DiRECT [8, 9]
Remission (year 2) intervention, % 35.6 28.2, 43.0 DiRECT [8, 9]
Remission (year 1) control, % 4.0 1.3, 7.4 DiRECT [8, 9]
Remission (year 2) control, % 3.4 0.7, 6.7 DiRECT [8, 9]
Relapse (year 2), % 28.4 18.7, 38.6 DiRECT [8, 9]
Mortality NRa NRa Walker et al [18]
Cost of intervention (year 1), £ 1137 1071, 1205 DiRECT [8, 9, 12, 17]
Cost of intervention (year 2, in remission), £ 356 302, 413 Current study
Other costs intervention arm (year 1), £ 689 537, 860 DiRECT [8, 9, 12, 17]
Other costs intervention arm (year 2), £ 936 691, 1209 Current study
Other costs control arm (year 1), £ 838 671, 1009 DiRECT [8, 9, 12, 17]
Other costs control arm (year 2), £ 1582 1135, 2073 Current study
Annual cost of diabetes: year 1, £ 1250 270 Roberts et al [21]
Annual cost of diabetes: increase per annum, % 6.7 Roberts et al [21]
HSU multiplier for diabetes 0.925 0.87, 0.96 Sullivan et al [20]
Distributions for probabilistic analysis: cost of diabetes, γ; HSU multiplier, β; mortality, β; other, bootstrap
HSU, health state utility
a Values are not reported due to the extent of data. See Walker et al [18] for the relevant data
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divided equally between years 1 and 2. The difference in the
total other non-intervention resource use (i.e. healthcare
contacts and hospitalisations) in year 1 was negligible [17]
and over the 2 years did not reach statistical significance;
however, these cost savings were significant in year 2 (£521;
95% CI £12, £1085).
Long-term cost-effectivenessAcross both arms of the trial, 79
participants achieved remission during the 2 year period,
including five who did so during year 2. Of 74 participants
in remission at year 1, 21 had relapsed by the end of year 2. At
this observed annual relapse rate in DiRECT (28%), mean
time to relapse would be approximately 3.5 years, with 13%
of participants expected to remain in remission beyond 5 years.
The resulting mean gain in life expectancy for a person in
remission at 1 year is 0.30, and, for all participants entered
in DiRECT, 0.13. Discounted QALYs were modelled to be
increased by 0.06. Total costs relating to diabetes (other than
ongoing intervention costs) were modelled, based on current
treatment costs, ranging from approximately £15,000 for
people remaining in remission until year 10 to £30,000 for
those not in remission after 1 year. After accounting in the
model for intervention costs and time to relapse, the interven-
tion generated a £1337 cost saving (95% CI £674, £2081) per
participant entered into the programme (Table 4). The inter-
vention therefore dominated standard care and had the proba-
bility of being both cost-saving and cost-effective at a thresh-
old of £20,000 per QALY of 1.00.
Follow-up of participants in DiRECT is continuing. As this
analysis relies on 2 year data we estimated time to total cost
equivalence (or break-even) and explored sensitivity to shorter
times to relapse. The model predicted the intervention would
become cost-saving overall after a period of 5–6 years under
base case assumptions for relapse (Fig. 2). Assuming all
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people who achieved remission relapsed after a maximum of
3 years, the intervention remained cost-saving due to deferred
diabetes (Table 5). Increasing the rate of relapse without
modifying the maximum period of remission had a lesser
impact on cost savings. The intervention also remained cost-
saving when a reduced rate of remission after 1 year was
Table 3 NHS resource use and costs over the first 2 years of the DiRECT trial
Resource use items Mean resource (SD) Mean difference
(95% CI)
Mean cost, £ (SD) Mean difference,
£ (95% CI)
Intervention
(n = 149)
Control
(n = 149)
Intervention (n = 149) Control (n = 149)
Counterweight-Plus intervention (a) 1411 (593) 0 1411 (1308, 1511)
Medications (sum of individual drug days)a
Oral glucose-lowering drugs (days) 290 (438) 910 (633) −620 (−738, −501) 90 (221) 321 (486) −231 (−314, −148)
Antihypertensive drugs (days) 381 (516) 782 (763) −410 (−537, −258) 15 (29) 41 (94) −26 (−42, −11)
Total cost of medications (b) 105 (222) 362 (486) −257 (−337, −173)
Other resource use
Primary and community care visits related to diabetes
GP 1.1 (1.6) 1.7 (2.0) −0.6 (−1.0, −0.2) 39 (58) 62 (75) −24 (−38, −9)
Practice nurse 3.5 (3.2) 4.0 (2.6) −0.6 (−1.2, 0.2) 37 (34) 43 (28) −6 (−13, 2)
Healthcare assistant 0.8 (1.4) 0.9 (1.3) −0.05 (−0.3, 0.3) 3.3 (5.6) 3.4 (5.1) −0.2 (−1.4, 1.1)
Community care 0.8 (1.1) 0.7 (1.4) 0.09 (−0.2, 0.4) 32 (47) 34 (74) −2.2 (−17, 11)
Primary and community care visits not related to diabetes
GP 7.8 (8.5) 8.2 (9.6) −0.4 (−2.3, 1.6) 285 (311) 301 (352) −16 (−86, 59)
Practice nurse 1.7 (2.5) 2.4 (3.5) −0.8 (−1.5, −0.1) 18 (27) 26 (37) −8.6 (−16, −1.2)
Healthcare assistant 0.3 (0.9) 0.6 (1.9) −0.3 (−0.6, −0.01) 1.3 (3.5) 2.5 (7.5) −1.2 (−2.5, −0.1)
Community care 0.6 (1.4) 0.5 (2.3) 0.09 (−0.3, 0.5) 31 (71) 26 (120) 5.7 (−17, 27)
Outpatient visits 3.2 (4.1) 4.0 (5.1) −0.8 (−1.8, 0.2) 500 (740) 594 (823) −94 (−271, 86)
Hospitalisationb 0.7 (2.5) 2.1 (9.4) −1.4 (−3.1, 0.01) 573 (1699) 966 (3109) −392 (−964, 119)
Total cost of other resource use (c) 1519 (2242) 2058 (3665) −539 (−1231, 84)
Total cost of resource use (b+c) 1624 (2268) 2420 (3690) −796 (−1465, −150)
Total 2 year cost (a+b+c) 3036 (2346) 2420 (3690) 616 (−45, 1269)
a Aggregate drug days over all medications
b Cost of hospitalisation was estimated by matching reason for admission and recorded length of stay in DiRECT to the appropriate NHS reference cost
(excluding excess bed-days where length of stay recorded in DiRECT exceeded the national average)
Table 4 Cost-effectiveness
results: 2 year and lifetime
analyses
Analysis Intervention Control Incremental 95% CI
2 years
Proportion of remission, % 35.6 3.4 32.3 23.5, 40.3
Costs, £ 3036 2420 616 −45, 1269
Cost per 2 year remission, £ 1907 Dominates, 4212
Lifetime
Life-years 24.03 23.89 0.13 0.09, 0.20
QALYs 11.27 11.22 0.06 0.04, 0.09
Costs, £
Intervention 1628a 1628 1439, 1835
Disease 31,319 34,283 −2964 −3706, −2308
Total 32,947 34,283 −1337 −2081, −674
Cost per QALY Cost saving: intervention dominates
a Total lifetime intervention cost including costs modelled for remission beyond year 2
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assumed, and with a shorter time horizon for analysis. In these
cases, although QALY gains were also reduced, the interven-
tion remained dominant.
Relapses were more frequent among women than among
men in year 2. When the analysis was performed using sex-
specific relapse rates, the overall QALY gain and cost were
little different, although health gains and cost savings were
more concentrated in men.
Assuming no detrimental impact of diabetes on QoL result-
ed in an increased QALY gain, the result of life expectancy
being valued more highly. The model assumed that type 2
diabetes, with a diagnosis at about 55 years of age, and without
intervention, would reduce life expectancy by 3.2 years in men
and by 5.2 years in women. Reducing mortality rates for
people with diabetes by 10% reduces the QALY gains from
intervention to approximately 0.05. The intervention remained
cost-saving both when excluding other healthcare cost savings
in the early period and when substantially lower long-term
costs due to diabetes were assumed.
Discussion
It is most unusual to be able to provide a new medical treat-
ment for a major chronic disease which is both health-
improving and cost-saving. The DiRECT study has shown
that durable remissions of type 2 diabetes to a non-diabetic
state can be achieved through an integrated weight manage-
ment programme, mostly for those achieving weight loss
>10 kg, for almost half of all participants. Weight loss
>15 kg in the intervention arm led to remissions for 86% at
1 year and 82% at 2 years [9]. The present analysis indicates
that the intervention is likely to generate QALY gains and be
not only cost-effective but also cost-saving after 5–6 years.
Given the rate at which second-line glucose-lowering medica-
tion costs have been rising in recent years, cost-saving esti-
mates may be conservative.
Although individuals with remissions are assumed to relapse
to diabetes over time, cost savings were modelled to accrue
beyond the point of relapse, with a delay in the requirement
for more intense resource use due to diabetic complications.We
have previously noted that roll-out of the intervention in routine
practice may provide for efficiencies that could reduce costs;
however, even under trial conditions, set-up costs are a minor
component of total intervention costs, and no adjustment was
made for such efficiencies in the present analysis.
Table 5 Cost-effectiveness under
alternative scenarios Base case assumptions Scenario Incremental
QALY Cost (£)
Base case result – 0.059 −1337
All participants relapsed by 10 years 5 years 0.045 −839
3 years 0.027 −165
Relapse rate as observed in trial Accelerated relapse rate (×1.2) 0.053 −1117
Analysis time horizon – lifetime 10 years 0.027 −637
Remission rate as observed in trial Year 1 remission rate × 0.8 0.047 −1001
Diminished QoL due to diabetes No impact of diabetes 0.064 −1337
Double impact of diabetes 0.054 −1337
Mixed population Men only 0.080 −1864
Women only 0.036 −847
SCI-Diabetes mortality (with diabetes) Plus 10% 0.071 −1285
Less 10% 0.047 −1391
Long-term diabetes costs Plus 50% 0.059 −2421
Less 50% 0.059 −252
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There were fewer medical appointments for intercurrent
medical problems in the DiRECT intervention group and
fewer serious adverse events in year 2 [9]. This is in line with
improved diabetes control and remissions for many. Better
QoL would therefore be expected, and this was borne out by
a general pattern of modestly improved EuroQol EQ-5D
scores in the intervention group at both 12 and 24 months.
[9] However, the mean duration of diabetes at baseline, of
3 years, is too short for the full impact of diabetes and its
complications to have already impaired QoL. Therefore,
QoLmeasurements over a 2 year period so early in the disease
course cannot be expected to capture the long-term impact of
more sustained diabetes remissions. Given that diabetes ulti-
mately carries a major long-term burden for health-related
QoL, we calculated QALY losses using a health state utility
decrement due to diabetes based on the US Medical
Expenditure Panel Survey [20]. Long-term health gains in
our analysis are, however, attributable principally to improved
life expectancy due to periods of remission, as our model
assumed, perhaps conservatively, that over time all individ-
uals in remission would return to the diabetes state by
10 years.
In the analysis of the Scottish Care Information Diabetes
Database (SCI-Diabetes), life expectancy was found to be
significantly lower in people with type 2 diabetes, irrespective
of age group or socioeconomic status (with the exception of
men >80 years in the most deprived quintile) [18]. These
published Scottish survival rate data, on which estimates of
life expectancy losses were based, are somewhat more conser-
vative than the estimates from a large European study [22],
which indicated that the years of life lost for people without
known vascular disease would be about 5.2 years for men and
6.1 years for women.
An important assumption in our analysis was that remission
returned participants to a life expectancy similar to that of the
diabetes-free population. However, the benefit in terms of
reduced mortality risk was modelled to be temporary, as all
individuals in remission were assumed to relapse to diabetes
within 10 years, andmanywere assumed to do sowithin 5 years.
As yet, there are no published data from any country on the
future health or life expectancy of people who achieve dietary–
weight-loss-induced remissions of type 2 diabetes. Many of the
participants in remission from diabetes inDiRECThadHbA1c in
the range of ‘prediabetes’ (42–48mmol/mol [6.0–6.5%]). About
30–40% of the adult population have HbA1c in this range, which
is associated with progression to type 2 diabetes for perhaps a
fifth, and poorer health outcomes than with lower HbA1c
[23–25]. The health outcomes for people in this range, which
may be considered ‘post-diabetes’, after improving diet and life-
style, are still unknown: they may be worse or better than those
of the general population.
No subgroup effects have been proposed clinically, and we
did not seek to do so. Relapse to diabetes in year 2, however,
was significantly more likely among women than among men
(p= 0.016). The SCI-Diabetes analysis found that women with
diabetes lost more years of life compared with men [18]. A
very large European study found a similar difference between
sexes [22].When we performed separate analyses for men and
women, however, we modelled greater life expectancy gains
in men than in women because of the lower rates of relapse in
men, though life-year and QALY gains remained statistically
significant for both; the intervention was cost-saving in both
men and women, and the noted difference in relapse could be
due to chance. These results should not imply withholding
treatment for women, as they still did very well, but there
may be benefit from modifying the intervention in the future
to better support maintenance of weight loss and diabetes
remission in women.
The present analysis is based on UK data both in terms of
the DiRECT trial itself, and other data for costs of diabetes
care under the NHS, and observed long-term mortality.
Intervention costs in other countries may differ; though, as
noted above, more efficient delivery, both in the UK and else-
where, might be expected once the programme is established
in routine practice. The major element of intervention cost is
the formula diet, whose acquisition cost might fall in the future
through economies of scale. Costs of routine diabetes care
under clinical guidelines may be expected to increase with
wider and earlier use of newer medications and an increasing
duration of disease after younger onset.
A 2019 position statement issued by the joint Association
of British Clinical Diabetologists and the Primary Care
Diabetes Society [5] reviewed the current evidence for remis-
sion of type 2 diabetes, ranging from bariatric surgery, in 1987
[26], to the most recent evidence of dietary and behavioural
interventions including DiRECT [9, 27, 28]. It concluded
there was ample evidence to support the recommendation of
achieving remission through weight loss, but that long-term
follow-up was needed given the risk of weight regain. Relapse
into diabetes, driven by weight regain, incurs costs from
relapse management and from resumption of progressive costs
for diabetes and its complications. Though relapse had a bear-
ing on outcomes in our study, even relatively rapid relapse did
not alter the conclusion that the low-energy diet intervention
was capable of producing long-term health gains without
adding long-term costs. The Counterweight-Plus intervention
may therefore be expected to be transferable to other diabetes
care settings in a similarly cost-effective manner.
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